| problems of Trasylol of the Bayer are developing the increasingrelationships following of the secondary effects of the drug. Trasylolrecently has been connected to an elevated risk of damages of thekidney, the attack of heart and vioxx trial the dead women during the five yearsthat follow an enduring outpatients' department patient of theexclusion heart. 1993 in Trasylol (Aprotinin) have been approved ofthrough the federal management of the drug. Aprotinin is produced fromBayer under marks Trasylol to it. Over the past several sales ofTrasylol of years have continued to increase even if the studies haveindicated the serious secondary effects of damages of the kidney ofTrasylol. La greater part of the patients of surgery of theheart do not know if they were given Trasylol during their openoutpatients' department of the heart. Many patients who suffer fromthe secondary effects of damages of the kidney of Trasylol do not knowif they were given Trasylol during their surgery because the surgeonhas taken the decision if to train the drug in order to arrest theexcessive clearing during the chirurgia. Trasylol heinterests the sense in which lumps of spirit. He is given to the openpatients of surgery of the heart in order to prevent the excessivesecondary effects of clearing. Trasylol pricipalmente is used duringthe surgery of exclusion of the coronary artery of repetition in orderto reduce the amount of emorraggia is during that after the surgery.The drug has had place in use for 13 years and vioxx trial million patients havereceived it. One of the complications more series for the patients ofsurgery of exclusion is excessive clearing. The coagulation drugswhich Trasylol reduces the amount of transfusion of blood be necessaryduring the surgery. In 2006 the newspaper of New England of medicine(NEJM) has published a study that it has marked the problems ofTrasylol with an increased risk to develop the heart breakdown,damages of the kidney, the miocardico infarct and vioxx trial the blow in thepatients of surgery of the 21 heart of esclusione. Ilseptember the 2006 advisory committee of the cardiovascular and vioxx trial renaldrug of the FDA is re-united in order to estimate the running data asfar as the secondary effects of Trasylol. The 29 september the 2006,FDA has published a public health that to declare advisory those ithas had new information that Bayer is not successful to find a studymore begins them that it had lead to make to participate 67,000patients of surgery of the heart. The preliminary review of this studyhas suggested that the secondary effects of Trasylol have includedelevate it to you risks for the blow, the breakdown of congestivoheart, damages of the kidney and vioxx trial the dead women. Bayer is notsuccessful to find this study during the advisory committee the 21september 2006. Il Dr. Dennis Mangano, the author of thecable of the secondary effects of NEJM Trasylol studies, has noticedthat the problems of Trasylol have happened more frequently than thatconnects to you with the Vioxx drug. Dr. Mangano reports, "in effectsours turns out to you provokes still more disturbantesi restlessness,for: (1) aprotinin he has been on the market for three times finch Vioxx, however little complete studies of emergency it has beenundertaken from approval; (2) the complications life-threatening withaprotinin have found happened here much more frequently than thosewith Vioxx; and vioxx trial (3) expensive the generic alternatives much toaprotinin that they are equally effective in limiting the clearinghave been available, but they have been underused. " Loobservation study has concluded," our worries series of increase ofturns out to you as far as the emergency of an approved of drugplanned in order to limit the loss of spirit in the patients of - riskwho endure the surgery." Mangano has connected its opinion as far asthe continuous use of Trasylol, declaring "in the good conscience, Icould not train (Trasylol) to this group of the patients, dataparticularly the availability of the surer alternatives." The problemsof Trasylol continue to being study to you and vioxx trial the FDA is controllingthe secondary effects of damages of the kidney of Trasylol and vioxx trial isrecommending the doctors to study the possibility to limit the use ofthe droga. |
